Keep up to date with life at the Babraham Research Campus. Explore the latest news, opinion and events from the campus, our stakeholders, partners and the companies based here.
PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is delighted to welcome James Clark as Chief Technology Officer.
Bicycle Therapeutics today announced that the first patient has been dosed in the Phase I dose escalation of its Phase I/II study of BT5528, a BicycleToxin Conjugate (BTC) targeting tumour antigen EphA2, in patients with advanced solid tumours associated with EphA2 expression.
PhoreMost and Sentinel Oncology have expanded a collaboration to accelerate the progression of SOL686, a novel allosteric Polo-like kinase 1 (PLK1) inhibitor through preclinical development and IND enabling studies for the treatment of Glioma.
Sphere Fluidics, which is commercialising single cell analysis systems underpinned by its patented picodroplet technology, and Peak Analysis and Automation which supplies intelligent lab automation solutions, have announced a cell analysis collaboration.
With the second wave of its ‘Accelerate@Babraham’ life sciences bio-incubator programme well underway, the Babraham Research Campus has confirmed additional financial and mentoring support for the initiative from Mundipharma.
PredictImmune today announced the start of the PRECIOUS (Predicting Crohn’s and Colitis Outcomes in the United States) study, which it is jointly funding with the Crohn’s & Colitis Foundation.
Bicycle Therapeutics today announced that new preclinical data from BT7480, a potent tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing CD137 (4-1BB), will be presented at the Society for Immunotherapy of Cancer’s (SITC) 2019 Annual Meeting.
Bicycle Therapeutics today announced the appointment of Nigel Crockett, Ph.D., as the company’s Chief Business Officer, replacing Peter Leone. Dr. Crockett has more than 25 years of experience in global business development for biopharmaceutical companies.
Bicycle Therapeutics today announced that it will collaborate with Oxford University’s Oxford Drug Discovery Institute (ODDI) to use Bicycle® technology for the development of novel therapeutics for dementia.
PredictImmune today confirmed that it has entered into an exclusive commercial partnership with KSL Biomedical (KSL), to commercialise and provide PredictImmune’s prognostic test for inflammatory bowel disease (IBD), PredictSURE IBD™, throughout North America.
Chief Executive of Clinical and Strategic Partnerships at BenevolentAI Dr Jackie Hunter writes a piece for Pharma Boardroom on why the pharmaceutical industry has been slow to adopt artificial intelligence-based technologies and also makes a prediction for the industry’s future.
Meet Ashok, researcher at BenevolentAI, at EMNLP for an oral presentation about his latest paper co-authored with Sia Togia: Biomedical relation extraction with pre-trained language representations and minimal task-specific architecture.
Today, BioMed Realty, the leading provider of real estate solutions to the life science community, announced its two newly developed Babraham Research Buildings in Cambridge are more than 50% let or under offer, including leases to PetMedix Ltd and Mission Therapeutics Ltd.
Bicycle Therapeutics today announced the presentation of updated data from a Phase I/IIa trial conducted in collaboration with Cancer Research UK and evaluating BT1718 in an unselected group of patients with advanced solid tumours.
This event is mainly targeting protein and antibody researchers, bioanalysis research scientists and research groups with an interest in precision medicine, translational oncology and biomarkers.
Bicycle Therapeutics plc today announced that updated data from the Phase I dose escalation portion of the Phase I/IIa trial evaluating the Company’s lead asset BT1718 in patients with advanced solid tumors will be presented at the European Society of Medical Oncology (ESMO) 2019 Annual Congress.
The shortlist represents a showcase of the enormous talent in the Cambridge region across sectors from biotech to cleantech, artificial intelligence to agritech including companies from Babraham Research Campus.
Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T cell enhancing therapeutics, today announces that Stewart Kay has been appointed as the Company’s Chief Business Officer (CBO).
BenevolentAI today announced that it has signed a Framework Collaboration Agreement with Novartis Pharma AG (“Novartis”) to leverage BenevolentAI’s technology platform to interrogate clinical trial and experimental data.
Bicycle Therapeutics plc, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycles®) product platform, today reported financial results for the second quarter ended June 30, 2019 and provided a clinical update.
Institute researchers are part of a world-first research project that will unravel how human embryos develop in the first weeks and months after fertilisation, improving our understanding of fertility, birth defects and regenerative medicine.
Abzena announced it has successfully completed a technology transfer and scalability evaluation using the Synaffix technologies of GlycoConnect™ (antibody conjugation) and HydraSpace™ (highly polar spacer).
Bicycle Therapeutics today announced the successful completion of Oxurion’s Phase I clinical trial evaluating the safety and tolerability of a single intravitreal injection of THR-149, a novel Bicycle-based plasma kallikrein (PKal) inhibitor, in patients with diabetic macular edema (DME).
A fast, accurate and low-cost test for blood potassium levels, which can be used at home and has the potential to improve the safety, health and lifestyle of tens of millions of people worldwide, is being developed by Kalium Diagnostics.
PhoreMost is set for a transformative phase of expansion that will create a revolutionary drug discovery business capable of influencing new treatments across a range of disease areas and featuring some of the world’s most influential Pharma players.
F-star Therapeutics Ltd today announces the appointment of Darlene Deptula-Hicks, MBA as Chief Financial Officer (CFO), succeeding Tolga Hassan, who is appointed to serve as F-star’s Chief Operating Officer.
The Campus is going to be busy on Wednesday (May 15), with the one-day Babraham Investor Conference (BIC) immediately followed by the Accelerate@Babraham pitches, which gives five organisations the chance to work at Babraham for five months.
Bicycle Therapeutics today announced a collaboration with the Dementia Discovery Fund (DDF) to use Bicycle technology for the development of novel therapeutics for neurodegenerative diseases.
A long-term collaboration between AstraZeneca and BenevolentAI will bring the power of artificial intelligence and machine learning to bear in the hunt for new treatments for chronic kidney disease and idiopathic pulmonary fibrosis.
PolyProx Therapeutics will develop a new class of drugs, called Polyproxin™ molecules, that are able to selectively target tumour cells and trigger the natural degradation machinery contained within the cell to arrest tumour growth.
Start Codon has been launched with funding from keystone investors including Cambridge Innovation Capital, Babraham Bioscience Technologies, Genentech, a member of the Roche Group, Dr Jonathan Milner and Dr Ian Tomlinson.
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle™) product platform, announced today that Paul Beswick, Ph.D., Bicycle’s Director of UK Chemistry and IP, will present at the Research & Innovation 2019 conference.
PredictImmune today confirmed that it has entered into a commercial agreement with Addenbrooke’s hospital, part of Cambridge University Hospitals NHS Foundation Trust, to provide PredictSURE IBD™ to clinicians and gastroenterologists in the UK and Ireland.
Bicycle Therapeutics announced today that Bicycle scientists have been selected to present two oral presentations at the American Association for Cancer Research Annual Meeting in Atlanta.
PredictImmune today announced that the UK's National Institute for Health and Care Excellence (NICE) has published a Medtech Innovation Briefing (MIB) on the use of PredictSURE IBD™ in the prognosis of inflammatory bowel disease.
Now in its 10th year, the one-day Babraham Investor Conference (BIC) will bring together like-minded investors focused on early-stage and scale-up life science and med-tech opportunities across the UK and Europe.
Abzena announced its Cambridge UK site has brought together its extensive discovery, immunogenicity assessment, protein engineering, formulation, bioassay and analytical expertise to launch a developability assessment and optimization service.
The DAP evaluates new, cutting-edge medical diagnostic technologies, producing guidance to help people working in the NHS make efficient, cost-effective and consistent decisions about adopting new products.
The annual competition gives up to five ventures the opportunity to win access to facilities, and take part in a fast-paced programme of support, led by a hand-picked group of experienced academic and commercial life science experts.
PredictImmune today confirmed its latest patent grant in the US. The US patent is part of PredictImmune’s third family of intellectual property relating to methods for predicting autoimmune disease risk.
Bicycle Therapeutics today announced several key changes to its executive team, including the appointment of Peter B. Leone as Chief Business Officer and the promotion of Lee Kalowski, Chief Financial Officer, to the role of U.S. President.
PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced confirmation of its ISO 13485 certification.
The first ever life science bio-incubator programme competition at the Babraham Research Campus, Accelerate@Babraham, has ended on a high for the competition winners with the promise of ongoing mentoring and an invitation to present at the renowned Babraham Investor Conference in 2019.
PredictImmune, developer of prognostic tools to guide treatment of patients with immune-mediated diseases, announced today that it has been awarded a grant of £100,000 by Innovate UK, the UK’s innovation agency.
PredictImmune today announced CE IVD (European Conformity In-Vitro Diagnostic Medical Devices) certification for its prognostic biomarker test for IBD, PredictSURE IBD™ - the first validated biomarker based prognostic test in inflammatory disease.
Additional company presentation will highlight preclinical research supporting the development of CD137 Bicycle® agonists as novel cancer immunotherapies.
Life science start-ups are invited to apply for one of up to five prizes that include a cash prize and access to the Babraham Research Campus bio-incubator facilities and much more...
PredictImmune, a developer of prognostic tools to guide treatment of patients with immune-mediated diseases, announced today that it has been awarded £4.3m by the Wellcome Trust.
The Babraham Research Campus is delighted to announce the appointment of Dr Karolina Zapadka as Business Acceleration Manager for the Babraham Research Campus’ bio-incubator and life science accelerator, Accelerate@Babraham.
One Nucleus is delighted to announce the appointment of Derek Jones as a Non-Executive Director. Derek is Chief Executive of Babraham Bioscience Technologies Ltd (BBT), the organisation responsible for the development and management of the Babraham Research Campus.
Accelerate@Babraham is designed to support the earliest stages of new life-science ventures, by providing easy-access laboratory and office space, (the ‘bio-incubator’) together with supporting programmes (the ‘accelerator’).
Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, provides an update on its UK and US facilities.
In October 2017, we were delighted to launch our partnership with BioMed Realty. This collaboration will see a new 108,000 square foot scale-up research space for growing bioscience-based companies built on site. Watch the launch video to find out more.
Biosceptre has received over £8M into its’ series A raise which will be used to resource the next stage of the companies’ development; progression into the clinic of Biosceptre’s first systemic products against novel oncology target nfP2X7.
Sixth Element Capital LLP (6EC), a UK based fund manager established to manage investments for the £70 million CRT Pioneer Fund, announces a £3 million investment in NeoPhore Ltd, a spin out from Cambridge, UK based PhoreMost Ltd.
Evelyn Warner, Editor of LaBiotech.eu, a leading digital media publisher covering the European Biotech industry interviews Derek Jones, Chief Executive of Babraham Bioscience Technologies (BBT) to talk about strategies for biotech startups.
Behind every successful meeting, lies the perfect venue. This can often be overlooked while you’re focussing on the smaller details of the day. If you’re responsible for coordinating your organisation’s next conference, or seminar, choosing the right space will be crucial to it's success.
As part of the UK’s £64B life sciences sector Babraham Bioscience Technologies, (BBT), welcomes the publication of Prof. Sir John Bell’s Life Science Industrial Strategy to the UK Government.
Cambridge Epigenetix (CEGX) and NuGEN Technologies, today announced that they have entered into a partnership agreement to integrate the CEGX TrueMethyl technology for oxidative bisulfite sequencing (oxBS-Seq) with NuGEN’s innovative NGS library preparation kits.
We are keen to promote the work that we do, telling the story of the Babraham Research Campus and the organisations that are based here. If you are interested in running a story, using our images or films or want to discuss an interview or potential collaboration opportunity we would be very pleased to hear from you. Please contact Sarah at Limewash to discuss your requirements
Sarah Brereton, Director, Limewash
01223 813 557, firstname.lastname@example.org
(+44) 1223 496 000
Babraham Bioscience Technologies Ltd
Babraham Research Campus
CB22 3AT, United Kingdom
01223 813 557